| Pharmaceutical Information |
| Drug Name |
Phenoxybenzamine |
| Drug ID |
BADD_D01754 |
| Description |
An alpha-adrenergic antagonist with long duration of action. It has been used to treat hypertension and as a peripheral vasodilator. |
| Indications and Usage |
For the treatment of phaeochromocytoma (malignant), benign prostatic hypertrophy and malignant essential hypertension. |
| Marketing Status |
approved |
| ATC Code |
C04AX02 |
| DrugBank ID |
DB00925
|
| KEGG ID |
D08358
|
| MeSH ID |
D010643
|
| PubChem ID |
4768
|
| TTD Drug ID |
D0X2DK
|
| NDC Product Code |
69988-0016 |
| UNII |
0TTZ664R7Z
|
| Synonyms |
Phenoxybenzamine | Phenoxybenzamine Hydrochloride | Hydrochloride, Phenoxybenzamine | Dibenzyline | Dibenzylin | Dibenyline | Dibenylene | Dibenziran | Dibenzyran |
|
| Chemical Information |
| Molecular Formula |
C18H22ClNO |
| CAS Registry Number |
59-96-1 |
| SMILES |
CC(COC1=CC=CC=C1)N(CCCl)CC2=CC=CC=C2 |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
